Invivyd (IVVD) FCF Margin (2024 - 2025)
Invivyd's (IVVD) quarterly FCF Margin came in at 89.82% in Q4 2025, up 12865.0% on a YoY basis from N/an in Q4 2024, and down 42.94% quarter-over-quarter from 62.84% in Q3 2025.
Powered by 
Analysis
Invivyd (IVVD) FCF Margin (2024 - 2025) Analysis & Trends
Invivyd (IVVD) has reported FCF Margin for 2 consecutive years, with 89.82% the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin rose 12865.0% year-over-year to 89.82%; the trailing twelve-month figure through Dec 2025 stood at 109.1% (up 56199.0% YoY), and the FY2025 full-year result was 109.1%, up 56199.0% from the prior year.
- FCF Margin declined to 89.82% in Q4 2025 per IVVD's latest filing, from 62.84% in the prior quarter.
- Across five years, FCF Margin topped out at 62.84% in Q3 2025 and bottomed at 1834.05% in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 14.91% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -22.35% |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -89.82% |
| Sep 30, 2025 | -62.84% |
| Jun 30, 2025 | -112.95% |
| Mar 31, 2025 | -188.19% |
| Dec 31, 2024 | -218.47% |
| Sep 30, 2024 | -502.57% |
| Jun 30, 2024 | -1,834.05% |